Can a common antibiotic stop pouchitis from coming back?

NCT ID NCT06312683

Recruiting now Prevention Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time

Summary

This trial tests whether taking the antibiotic rifaximin daily for a year can prevent recurrent pouchitis—inflammation of the J-pouch—after an initial episode in people who had surgery for ulcerative colitis. All participants will receive rifaximin twice a day for up to 365 days. The study will see if people are willing to take it long-term and if it reduces the chance of a second episode, while also monitoring for unexpected side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: rifaximin (an antibiotic, brand name Xifaxan)
What this could lead to: If it works, this could point toward a way to prevent recurrent pouchitis in people who have had surgery for ulcerative colitis.
What could go wrong: This is a small, early-phase study with only 16 participants, so results may not apply broadly. Rifaximin may cause side effects or may not effectively prevent recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POUCHITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pouchitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POUCHITIS

Contacts and locations

Locations

NYU IBD Center
RECRUITING

New York, New York, 10016, United States
University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27599, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.